Orion Portfolio Solutions LLC Trims Stake in Insulet Co. (NASDAQ:PODD)

Orion Portfolio Solutions LLC lessened its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 30.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,453 shares of the medical instruments supplier's stock after selling 2,373 shares during the quarter. Orion Portfolio Solutions LLC's holdings in Insulet were worth $1,424,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Intech Investment Management LLC bought a new position in Insulet in the 3rd quarter worth approximately $224,000. Glenmede Trust Co. NA lifted its position in shares of Insulet by 2.3% during the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier's stock worth $484,000 after acquiring an additional 47 shares in the last quarter. Public Sector Pension Investment Board boosted its holdings in shares of Insulet by 14.8% in the third quarter. Public Sector Pension Investment Board now owns 3,099 shares of the medical instruments supplier's stock worth $721,000 after acquiring an additional 400 shares during the period. Captrust Financial Advisors grew its position in shares of Insulet by 5.1% in the third quarter. Captrust Financial Advisors now owns 1,760 shares of the medical instruments supplier's stock valued at $410,000 after purchasing an additional 86 shares in the last quarter. Finally, Holocene Advisors LP raised its stake in shares of Insulet by 1.0% during the 3rd quarter. Holocene Advisors LP now owns 14,986 shares of the medical instruments supplier's stock valued at $3,488,000 after purchasing an additional 154 shares during the period.

Remove Ads

Insulet Trading Down 3.6 %

Shares of PODD traded down $9.19 during trading hours on Tuesday, hitting $247.04. The company had a trading volume of 1,050,850 shares, compared to its average volume of 715,990. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock's 50 day moving average price is $268.29 and its 200 day moving average price is $259.98. The firm has a market cap of $17.35 billion, a P/E ratio of 42.67, a P/E/G ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, research analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. upped their price target on Insulet from $280.00 to $330.00 and gave the company an "overweight" rating in a research report on Thursday, December 12th. Piper Sandler boosted their price target on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Wells Fargo & Company increased their price objective on Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Citigroup boosted their target price on Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Stifel Nicolaus raised their price target on Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $292.06.

Insider Buying and Selling at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares in the company, valued at $888,525. The trade was a 36.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.